---
title: U.S. Anti-Doping Agency
description: 
published: true
date: 2025-09-22T21:39:42.997Z
tags: 
editor: markdown
dateCreated: 2025-09-22T21:39:38.878Z
---

# U.S. Anti-Doping Agency

### Funding

**2021: Fitzpatrick Voted To Increase Funds For The U.S. Anti-Doping
Agency Starting In FY 2022 From \$15.5 Million To \$23.7 Million By FY
2030.** In April 2021, Fitzpatrick voted for the United States
Anti-Doping Agency Reauthorization Act which would, according to
Congressional Quarterly, "reauthorize the U.S. Anti-Doping Agency
through fiscal 2030, authorizing \$15.5 million for fiscal 2022,
incrementally increasing to \$23.7 million for fiscal 2030." The vote
was on passage. The House passed the bill by a vote of 381-37. The
Senate did not take substantive action on the bill. \[House Vote 99,
[4/14/21](http://clerk.house.gov/evs/2021/roll099.xml); Congressional
Quarterly, [4/14/21](https://plus.cq.com/vote/2021/H/99?15);
Congressional Actions, [H.R.
172](https://www.congress.gov/bill/117th-congress/house-bill/172/actions)\]

-   **The Bill Would Have Certified The Testing Of International
    Athletes Participating In U.S. Competitions And Provided Educational
    Information To Athletes, Parents And Coaches On Integrity, Character
    Building And Healthy Performances.** According to Congressional
    Quarterly, "task the agency with certifying the testing of
    international athletes competing in the U.S. and with promoting a
    'positive youth sport experience' by providing educational materials
    on sportsmanship, character building and healthy performance for
    athletes, parents and coaches." \[Congressional Quarterly,
    [4/14/21](https://plus.cq.com/vote/2021/H/99?15)\]

-   **The Bill Would Have Required Several Federal Agencies To
    Collaborate With The U.S. Anti-Doping Agency By Sharing Information
    Regarding Performance-Enhancing Drug Prohibition And Prevention.**
    According to Congressional Quarterly, "require the Judiciary
    Department, Homeland Security Department, and Food and Drug
    Administration to coordinate with the agency by sharing information
    related to prohibiting or preventing the use of
    performance-enhancing drugs or methods." \[Congressional Quarterly,
    [4/14/21](https://plus.cq.com/vote/2021/H/99?15)\]